Systemic administration of the antisense oligonucleotide NS‐089/NCNP‐02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trial

Systemic administration of the antisense oligonucleotide NS‐089/NCNP‐02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trial

Abstract Aim The purpose of this study is to evaluate the safety and pharmacokinetics of the novel morpholino oligomer NS‐089/NCNP‐02 which can induce exon 44 skipping, in patients with DMD. Additionally, we aimed to identify markers predictive of therapeutic efficacy and determine the optimal dosin...

Full description

Bibliographic Details
Main Authors: Takami Ishizuka, Hirofumi Komaki, Yasuko Asahina, Harumasa Nakamura, Norio Motohashi, Eri Takeshita, Yuko Shimizu‐Motohashi, Akihiko Ishiyama, Chihiro Yonee, Shinsuke Maruyama, Eisuke Hida, Yoshitsugu Aoki
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:Neuropsychopharmacology Reports
Subjects:
antisense oligonucleotide
DMD
Duchenne muscular dystrophy
exon 44
exon‐skipping
first‐in‐human study
Online Access:https://doi.org/10.1002/npr2.12335

Internet

https://doi.org/10.1002/npr2.12335

Similar Items